AN2 Therapeutics, Inc. (ANTX)

Market Cap	31.68M
Revenue (ttm)	n/a
Net Income (ttm)	-45.35M
Shares Out	30.18M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,585
Open	1.050
Previous Close	1.060
Day's Range	1.050 - 1.070
52-Week Range	0.870 - 3.070
Beta	-0.08
Analysts	Buy
Price Target	2.00 (+90.48%)
Earnings Date	Aug 12, 2025

About ANTX

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2022
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: ANTX
• Website: https://www.an2therapeutics.com

Analyst Summary

According to 3 analysts, the average rating for ANTX stock is "Buy." The 12-month stock price target is $2.0, which is an increase of 90.48% from the latest price.

Price Target

$2.0

(90.48% upside)

Analyst Consensus: Buy